A Phase 3, Randomized, Double-Blind, Placebo-Controlled,Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia.

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled,Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2016

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 19 Apr 2016 Results of a pooled analysis from four trials (n= 1462) published in the Journal of Urology
    • 24 Aug 2015 Results of post-hoc analysis of pooled data from four trials published in the International Journal of Clinical Practice.
    • 01 Nov 2011 Results published in the European Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top